Treatment with docetaxel in combination with Aneustat leads to potent inhibition of metastasis in a patient-derived xenograft model of advanced prostate cancer

BACKGROUND: Docetaxel used for first-line treatment of advanced prostate cancer (PCa) is only marginally effective. We previously showed, using the LTL-313H subrenal capsule patient-derived metastatic PCa xenograft model, that docetaxel combined with Aneustat (OMN54), a multivalent plant-derived the...

Descripción completa

Detalles Bibliográficos
Autores principales: Qu, Sifeng, Ci, Xinpei, Xue, Hui, Dong, Xin, Hao, Jun, Lin, Dong, Clermont, Pier-Luc, Wu, Rebecca, Collins, Colin C, Gout, Peter W, Wang, Yuzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877435/
https://www.ncbi.nlm.nih.gov/pubmed/29381682
http://dx.doi.org/10.1038/bjc.2017.474

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877435/
https://www.ncbi.nlm.nih.gov/pubmed/29381682
http://dx.doi.org/10.1038/bjc.2017.474

Ejemplares similares